Dermira (Dermira) Debt-to-Equity : 25.37 (As of Sep. 2019)

View and export this data going back to 2014. Start your Free Trial

What is Dermira Debt-to-Equity?

Dermira's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was $4.26 Mil. Dermira's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was $363.12 Mil. Dermira's Total Stockholders Equity for the quarter that ended in Sep. 2019 was $14.48 Mil. Dermira's debt to equity for the quarter that ended in Sep. 2019 was 25.37.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Dermira's Debt-to-Equity or its related term are showing as below:

DERM's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.145
* Ranked among companies with meaningful Debt-to-Equity only.

Dermira Debt-to-Equity Historical Data

The historical data trend for Dermira's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermira Debt-to-Equity Chart

Dermira Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Debt-to-Equity

Get a 7-Day Free Trial

0.01

1.87

-38.32

Dermira Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Debt-to-Equity	Get a 7-Day Free Trial															5.21	-38.32	4.41	5.01	25.37

Competitive Comparison of Dermira's Debt-to-Equity

For the Biotechnology subindustry, Dermira's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dermira's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dermira's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Dermira's Debt-to-Equity falls into.

Dermira Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Dermira's Debt to Equity Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(32.566	+	313.789)	/	-9.039
	=	-38.32

Dermira's Debt to Equity Ratio for the quarter that ended in Sep. 2019 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.255	+	363.123)	/	14.48
	=	25.37

Dermira (NAS:DERM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Dermira Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Dermira's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Dermira (Dermira) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermira Inc (NAS:DERM) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Middlefield Road, Suite 150, Menlo Park, CA, USA, 94025

Website

http://www.dermira.com

Dermira Inc is a biopharmaceutical company focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States.The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne.

Executives

Halley E Gilbert	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
William R Ringo	director
Fred B Craves	director	750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
David E Cohen	director	3160 PORTER DRIVE, PALO ALTO CA 94304
Thomas G Wiggans	director, officer: CEO & Chairman of the Board
Jason Raleigh Nunn	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
Andrew Guggenhime	officer: CFO	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Lori Lyons-williams	officer: Chief Commercial Officer	C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Kathleen Sebelius	director	C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Eugene A Bauer	director, officer: Chief Medical Officer	C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Lilly Eli & Co	10 percent owner	LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Mark Mcdade	director	C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Matthew K Fust	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Canaan Partners Viii Llc	director	285 RIVERSIDE AVE, STE 250, WESTPORT CT 06880
Canaan Viii Lp	director	2765 SAND HILL RD, MENLO PARK CA 94025